Shanthi Mogali, MD
Assistant Professor of PsychiatryCards
Appointments
Additional Titles
Chair of Psychiatry, Lawrence and Memorial Hospital, Department of Behavioral Health and Psychiatry
Chair of Psychiatry, Westerly Hospital, Department of Behavioral Health and Psychiatry
Contact Info
Appointments
Additional Titles
Chair of Psychiatry, Lawrence and Memorial Hospital, Department of Behavioral Health and Psychiatry
Chair of Psychiatry, Westerly Hospital, Department of Behavioral Health and Psychiatry
Contact Info
Appointments
Additional Titles
Chair of Psychiatry, Lawrence and Memorial Hospital, Department of Behavioral Health and Psychiatry
Chair of Psychiatry, Westerly Hospital, Department of Behavioral Health and Psychiatry
Contact Info
About
Copy Link
Titles
Assistant Professor of Psychiatry
Chair of Psychiatry, Lawrence and Memorial Hospital, Department of Behavioral Health and Psychiatry; Chair of Psychiatry, Westerly Hospital, Department of Behavioral Health and Psychiatry
Appointments
Psychiatry
Assistant ProfessorPrimary
Other Departments & Organizations
- All Institutions
- Psychiatry
- Yale Medicine
- Yale New Haven Health System
Education & Training
- Non Degree Program
- Columbia University, Addiction Psychiatry (2011)
- Fellowship
- Columbia College of Physicians and Surgeons (2011)
- Non Degree Program
- Emory University School of Medicine, General Psychiatry
- Residency
- Emory University School of Medicine (2009)
- Internship
- Emory University School of Medicine (2006)
- MD
- Meharry Medical College (2005)
- BA
- Fisk University
Research
Copy Link
Overview
As a fellow, Dr. Mogali received pilot funding for her study examining microglial inhibitors in opioid abusers (manuscript in preparation for publication) and completed a secondary analysis of data collected to determine demographic factors of patients that may predict completion of a rapid naltrexone detoxification. As an Instructor, Dr. Mogali co-authored a chapter on Treatment of Pain and Opioid Use in the textbook, "Research and Development of Opioid-Related Ligands" and co-authored a review article on combination drug use of opioids, benzodiazepine and alcohol. She received mentorship in opioid research in the human laboratory setting under Dr. Sandra Comer, Ph.D. Dr. Mogali served as the research psychiatrist for the opioid laboratory at Columbia University. Her research interests include medication development and opioid self-administration studies that may influence treatment of opioid use disorders.
Research at a Glance
Publications Timeline
Publications
2022
Gabapentin increases the abuse liability of alcohol alone and in combination with oxycodone in participants with co-occurring opioid and alcohol use disorder
Castillo F, Jones J, Luba R, Mogali S, Foltin R, Evans S, Comer S. Gabapentin increases the abuse liability of alcohol alone and in combination with oxycodone in participants with co-occurring opioid and alcohol use disorder. Pharmacology Biochemistry And Behavior 2022, 221: 173482. PMID: 36244527, PMCID: PMC10117180, DOI: 10.1016/j.pbb.2022.173482.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsAlcohol use disorderOpioid use disorderAbuse liabilityUse disorderNon-treatment seeking participantsTest sessionsVisual analog scalePositive subjective responsesPlacebo-controlled crossover studyVisual analog scale ratingsEffects of oxycodoneSubjective effectsDrug challengeWithin-subjectEffect of gabapentinSubjective responsesDrug likenessHigh riskHigher risk of adverse outcomesDouble-blindDisordersRisk of adverse outcomesPrimary outcome variablePhysiological effectsAbuseThe effects of acute oral naltrexone pretreatment on the abuse potential of intranasal methamphetamine, and the relationship between reward/punishment sensitivity and methamphetamine’s effects
Jones J, Mumtaz M, Vadhan N, Martinez S, Pramanik S, Manubay J, Mogali S, Perez F, Castillo F, Kranzler H, Comer S. The effects of acute oral naltrexone pretreatment on the abuse potential of intranasal methamphetamine, and the relationship between reward/punishment sensitivity and methamphetamine’s effects. Behavioural Pharmacology 2022, 33: 255-265. PMID: 35438671, PMCID: PMC9149033, DOI: 10.1097/fbp.0000000000000671.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsMethamphetamine self-administrationIntranasal methamphetamineMethamphetamine use disorderReward/punishment sensitivitySelf-AdministrationNaltrexone pretreatmentAbuse potentialUse disorderReinforcing effectsSubjective ratingsSelf-administration taskPositive subjective effectsProbabilistic categorization taskEffects of naltrexoneEffects of methamphetamineOpioid antagonist naltrexoneStand-alone medicationMethamphetamine effectsSubjective effectsAntagonist naltrexoneCategorization taskNaltrexoneTest sessionsMethamphetaminePsychostimulant users
2021
Minocycline attenuates oxycodone-induced positive subjective responses in non-dependent, recreational opioid users
Mogali S, Askalsky P, Madera G, Jones JD, Comer SD. Minocycline attenuates oxycodone-induced positive subjective responses in non-dependent, recreational opioid users. Pharmacology Biochemistry And Behavior 2021, 209: 173241. PMID: 34298029, PMCID: PMC8429209, DOI: 10.1016/j.pbb.2021.173241.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsAnalgesic effectRecreational opioid usersReceptor-selective agonistOpioid usersPreclinical studiesAbuse liabilityNew York State Psychiatric InstituteRelease of cytokinesPositive subjective effectsTetracycline antibiotic minocyclineYears of ageDouble-blind outpatient studyPositive subjective responsesGlial activationAcute administrationCertain medicationsHuman research volunteersOutpatient studyGlial cellsNon-treatment seekingSame dosesRewarding effectsOxycodoneDrug AdministrationMinocycline
2020
Effects of lorcaserin on oxycodone self-administration and subjective responses in participants with opioid use disorder
Brandt L, Jones J, Martinez S, Manubay J, Mogali S, Ramey T, Levin F, Comer S. Effects of lorcaserin on oxycodone self-administration and subjective responses in participants with opioid use disorder. Drug And Alcohol Dependence 2020, 208: 107859. PMID: 31980285, PMCID: PMC7063580, DOI: 10.1016/j.drugalcdep.2020.107859.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsCue-induced reinstatementOxycodone self-administrationSelf-AdministrationSubjective effectsOpioid use disorderAbuse liabilityUse disorderCue-induced reinstatement of drug-seeking behaviorReinstatement of drug-seeking behaviorAbuse liability of oxycodoneSubjective effects of oxycodoneNon-treatment-seeking volunteersWide dose rangeDrug-seeking behaviorVerbal choicesEffects of lorcaserinTwo-week testing periodEffects of oxycodoneProgressive-ratioCue exposureChoice sessionsLorcaserinReceptor agonistsInpatient trialSubjective responses
2019
Assessing the contribution of opioid- and dopamine-related genetic polymorphisms to the abuse liability of oxycodone
Jones J, Mumtaz M, Manubay J, Mogali S, Sherwin E, Martinez S, Comer S. Assessing the contribution of opioid- and dopamine-related genetic polymorphisms to the abuse liability of oxycodone. Pharmacology Biochemistry And Behavior 2019, 186: 172778. PMID: 31493434, PMCID: PMC6801039, DOI: 10.1016/j.pbb.2019.172778.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsEffects of oxycodoneAbuse liabilityCatechol-O-methyltransferaseSubjective effectsAbuse liability of oxycodoneSubjective effects of oxycodoneDopamine-related genetic polymorphismsIntense feelingsDopamine metabolizing enzymeLaboratory testing sessionsPositive subjective responsesResponses to opioid drugsAnalgesic effectCOMT rs4680 genotypeStimulating effectOpioid use disorderMaladaptive patternsGenetic polymorphismsContribution of opioidsAbuse potentialEffects of opioidsUse disorderRs4680 genotypeDose-dependent increasePrescription opioid exposure
2018
The PPARγ Agonist Pioglitazone Fails to Alter the Abuse Potential of Heroin, But Does Reduce Heroin Craving and Anxiety
Jones J, Bisaga A, Metz V, Manubay J, Mogali S, Ciccocioppo R, Madera G, Doernberg M, Comer S. The PPARγ Agonist Pioglitazone Fails to Alter the Abuse Potential of Heroin, But Does Reduce Heroin Craving and Anxiety. Journal Of Psychoactive Drugs 2018, 50: 390-401. PMID: 30204554, PMCID: PMC6487639, DOI: 10.1080/02791072.2018.1508789.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsPositive subjective effectsEffects of heroinHeroin cravingAbuse potentialSubjective effects of heroinHeroin-dependent participantsSelf-administered drugsTwo-week testing periodTest day 6Indicator of drug effectChoice procedureOverall anxietyThree-week studyRobust effectsPeroxisome proliferator-activated gamma receptorTest daysDrug effectsPreclinical modelsVerbal choicesHeroinTest weekCravingAnxietyActive heroinParticipants
2017
Pioglitazone, a PPARγ agonist, reduces nicotine craving in humans, with marginal effects on abuse potential
Jones J, Comer S, Metz V, Manubay J, Mogali S, Ciccocioppo R, Martinez S, Mumtaz M, Bisaga A. Pioglitazone, a PPARγ agonist, reduces nicotine craving in humans, with marginal effects on abuse potential. Pharmacology Biochemistry And Behavior 2017, 163: 90-100. PMID: 29020601, PMCID: PMC5959043, DOI: 10.1016/j.pbb.2017.10.002.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsAbuse potentialNicotine cigarettesPeroxisome proliferator-activated receptor agonistsCue exposure sessionsDe-nicotinized cigarettesSelf-administration taskMeasures of cravingPotential of nicotineAddictive drugsNicotine cravingHuman laboratoryExposure sessionsNicotine patchTest daysReceptor agonistsVerbal choicesDay participantsNicotineCravingAbuseMaintenance conditionsBrands of cigarettesParticipantsAgonistsFinger pressingAbuse liability of intravenous buprenorphine vs. buprenorphine/naloxone: Importance of absolute naloxone amount
Jones J, Manubay J, Mogali S, Metz V, Madera G, Martinez S, Mumtaz M, Comer S. Abuse liability of intravenous buprenorphine vs. buprenorphine/naloxone: Importance of absolute naloxone amount. Drug And Alcohol Dependence 2017, 179: 362-369. PMID: 28844013, PMCID: PMC10071507, DOI: 10.1016/j.drugalcdep.2017.06.033.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsSubjective effectsAversive effectsAbuse liabilityAbuse potentialPositive subjective effectsDegree of withdrawalIV heroinReinforcing effectsLaboratory sessionsBup/Nx dosesOral hydromorphoneIntravenous buprenorphineHeroinIV useBUPNegative controlDoseNXAbuseBuprenorphineBUP/NXWithdrawalPlaceboSessionsHydromorphoneEffects of Ibudilast on the Subjective, Reinforcing, and Analgesic Effects of Oxycodone in Recently Detoxified Adults with Opioid Dependence
Metz VE, Jones JD, Manubay J, Sullivan MA, Mogali S, Segoshi A, Madera G, Johnson KW, Comer SD. Effects of Ibudilast on the Subjective, Reinforcing, and Analgesic Effects of Oxycodone in Recently Detoxified Adults with Opioid Dependence. Neuropsychopharmacology 2017, 42: 1825-1832. PMID: 28393896, PMCID: PMC5520790, DOI: 10.1038/npp.2017.70.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsEffect of ibudilastVisual analog scaleAnalgesic effectOpioid dependenceEffects of oxycodoneGlial cell activationOpioid use disorderTreatment of asthmaDrug Effects QuestionnaireRecent preclinical studiesCold pressor testNonselective phosphodiesterase inhibitorMaintenance doseOxycodone administrationAnalog scaleWithdrawal symptomsDrug likingHeroin cravingPressor testMale volunteersPreclinical studiesIbudilastPatient detoxificationUse disordersOxycodone
2015
Patterns of opioid use and co-morbidity in non-treatment-seeking individuals with opioid use disorder
Manubay J, Comer S, Mogali S, Jones J, Metz V, Madera G, Luba R, Vogelman J, Sullivan M. Patterns of opioid use and co-morbidity in non-treatment-seeking individuals with opioid use disorder. Drug And Alcohol Dependence 2015, 156: e139. DOI: 10.1016/j.drugalcdep.2015.07.380.Peer-Reviewed Original ResearchCitations
Academic Achievements & Community Involvement
Copy Link
Clinical Care
Copy Link
Overview
Shanthi Mogali, MD, is a psychiatrist specializing in psychiatry and addiction medicine. She focuses on diagnosing and treating disorders related to addiction, including opioid use disorders. She offers treatments aimed at managing addiction-related conditions, supporting patient recovery, and improving mental health outcomes.
As an assistant professor of psychiatry at Yale School of Medicine, Dr. Mogali conducts research on medication development and studies related to opioid self-administration, aiming to improve treatment methods for opioid use disorders.
Dr. Mogali received her medical degree from Meharry Medical College, and pursued additional specialized training in general psychiatry at Emory University School of Medicine and addiction psychiatry at Columbia University.
Clinical Specialties
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileNews
Copy Link
Get In Touch
Copy Link
Contacts
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.